PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsMontelukast
Montelukast
Montelukast, Singulair (montelukast) is a small molecule pharmaceutical. Montelukast was first approved as Singulair on 1998-02-20. It is used to treat allergic rhinitis perennial and asthma in the USA. The pharmaceutical is active against cysteinyl leukotriene receptor 1. In addition, it is known to target uracil nucleotide/cysteinyl leukotriene receptor.
Download report
Favorite
COVID-19
Top Prescription Drugs
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
respiratory tract diseasesD012140
otorhinolaryngologic diseasesD010038
immune system diseasesD007154
Trade Name
FDA
EMA
Montelukast, Singulair (discontinued: Montelukast)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Montelukast sodium
Tradename
Company
Number
Date
Products
SINGULAIROrganonN-020829 RX1998-02-20
1 products, RLD, RS
SINGULAIROrganonN-020830 RX1998-02-20
2 products, RLD, RS
SINGULAIROrganonN-021409 RX2002-07-26
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
montelukastANDA2024-10-14
montelukast sodiumANDA2024-10-31
singulairNew Drug Application2024-10-15
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
R: Respiratory system drugs
— R03: Drugs for obstructive airway diseases
— R03D: Other systemic drugs for obstructive airway diseases in atc
— R03DC: Leukotriene receptor antagonists for obstructive airway diseases
— R03DC03: Montelukast
— R03DC53: Montelukast, combinations
HCPCS
No data
Clinical
Clinical Trials
354 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AsthmaD001249EFO_0000270J451529425034165
RhinitisD012220EFO_0008521J31632120757
Allergic rhinitisD065631—J30.9432119855
Healthy volunteers/patients———17——1220
Allergic rhinitis seasonalD006255EFO_0003956J30—1124118
BronchiolitisD001988HP_0011950——613515
CoughD003371HP_0012735R05—1—5410
Sleep apnea syndromesD012891HP_0010535G47.3—23329
Covid-19D000086382———34129
Allergic rhinitis perennialD012221EFO_1001417J30.89——72—9
Show 58 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Multiple myelomaD009101—C90.0142——7
Plasma cell neoplasmsD054219——142——7
Rheumatoid arthritisD001172EFO_0000685M06.9311——5
ArthritisD001168HP_0001369M05-M14311——5
Status asthmaticusD013224———32—14
Eosinophilic esophagitisD057765EFO_0004232K20.01—1—24
EsophagitisD004941HP_0100633K201—1—13
Communicable diseasesD003141———11——2
Sickle cell anemiaD000755EFO_0000697D57—21——2
Post-acute covid-19 syndromeD000094024————1—12
Show 21 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Alzheimer diseaseD000544EFO_0000249F03—2———2
Premature birthD047928EFO_0003917O60—2———2
Bronchopulmonary dysplasiaD001997—P27.811———2
Birth weightD001724EFO_0004344—11———2
Graft vs host diseaseD006086—D89.81—2———2
Non-small-cell lung carcinomaD002289———2———2
Interstitial lung diseasesD017563HP_0006530J84.89—1———1
Cryptogenic organizing pneumoniaD018549EFO_1001300J84.116—1———1
Organizing pneumoniaD000092124———1———1
Ovarian neoplasmsD010051EFO_0003893C56—1———1
Show 14 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MalnutritionD044342EFO_0008572E40-E467————7
Respiratory tract diseasesD012140——3————3
Respiration disordersD012120—J00-J993————3
ObesityD009765EFO_0001073E66.91———12
Hiv infectionsD015658EFO_0000764B202————2
Type 2 diabetes mellitusD003924EFO_0001360E111————1
Diabetes mellitusD003920HP_0000819E08-E131————1
OsteoarthritisD010003EFO_0002506M15-M191————1
Anterior cruciate ligament injuriesD000070598——1————1
Tibial meniscus injuriesD000070600——1————1
Show 4 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
EosinophiliaD004802HP_0001880D72.1————33
DyspepsiaD004415EFO_0008533K30————22
Nephrotic syndromeD009404EFO_0004255N04————11
NephrosisD009401——————11
Crest syndromeD017675—M34.1————11
DepressionD003863—F33.9————11
AnxietyD001007EFO_0005230F41.1————11
Gastroesophageal refluxD005764EFO_0003948K21————11
Chronic renal insufficiencyD051436—N18————11
Renal insufficiencyD051437HP_0000083N19————11
Show 15 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameMontelukast
INNmontelukast
Description
Montelukast is a member of quinolines, a monocarboxylic acid and an aliphatic sulfide. It has a role as a leukotriene antagonist, an anti-asthmatic drug and an anti-arrhythmia drug. It is a conjugate acid of a montelukast(1-).
Classification
Small molecule
Drug classantiasthmatics/antiallergics (not acting primarily as antihistamines): leukotriene receptor antagonists
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1
Identifiers
PDB—
CAS-ID158966-92-8
RxCUI—
ChEMBL IDCHEMBL787
ChEBI ID50730
PubChem CID5281040
DrugBankDB00471
UNII IDMHM278SD3E (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
CYP2C8
CYP2C8
Organism
Homo sapiens
Gene name
CYP2C8
Gene synonyms
NCBI Gene ID
Protein name
cytochrome P450 2C8
Protein synonyms
CYPIIC8, Cytochrome P450 form 1, Cytochrome P450 IIC2, Cytochrome P450 MP-12, Cytochrome P450 MP-20, cytochrome P450, family 2, subfamily C, polypeptide 8, cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 8, flavoprotein-linked monooxygenase, microsomal monooxygenase, P450 form 1, S-mephenytoin 4-hydroxylase, xenobiotic monooxygenase
Uniprot ID
Mouse ortholog
—
—
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Singulair – Organon
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Singulair – Merck & Co
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Montelukast
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 8,785 documents
View more details
Safety
Black-box Warning
Black-box warning for: Montelukast sodium, Singulair
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
35,290 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use